Skip to main content
. 2022 Aug 17;15:111. doi: 10.1186/s13045-022-01325-0

Table 1.

Comparison of properties of novel immune checkpoint modulators

Target Chromosomal location Binding partner Expression
VISTA 10q22.1 VSIG3 Myeloid cells, T cells
CD38 4p15.32 CD31 Non-hematopoietic cells, immune cells
CD39 10q24.1 Unknown B cells, NK cells, DCs, monocytes, macrophages, Tregs
CD73 6q14.3 Unknown endothelial cells, lymphocytes, tumor cells, stromal cells
LAG-3 12p13.31 MHC-II, galectin-3, LSECtin, a-synuclein, FGL1 Activated T cells, B cells, Tregs, NK cells, DCs
IDO-1 8p11.21 AhR DCs, eosinophils, tumor cells
CD27 12p13.31 CD70 T cells, B cells, plasma cells, NK cells
TIM-3 5q33.2 Galectin-9, Ceacam-1, HMGB1, PtdSer Activated T cells, B cells, Tregs, DCs, NK cells, monocytes
CD47 3q13.12 SIRPA Human cells, tumor cells
CD93 20p11.21 IL-17D Endothelial cells
CD161 12p13.31 LLT1 NK cells, T cells
BTLA 3q13.2 HVEM Mature B cells, T cells, Tregs, macrophages, DCs
VTCN1 1p13.1-p12 Unknow Antigen-presenting cells
B7-H3 15q24.1 Unknow Activated T cells, NK cells, DCs, monocytes, tumor cells
TIGIT 3q13.31 CD155, CD112, CD113 NK cells, activated T cells, Tregs, follicular T helper cells